eXoZymes announces role in $9.2M Meta-PURE initiative
eXoZymes' Role in Meta-PURE Initiative: eXoZymes is participating in the $9.2M Meta-PURE project, funded by the National Science Foundation, aimed at enhancing cell-free biomanufacturing through standardized modules for various applications, including nutraceuticals and pharmaceuticals.
Innovative Cell-Free Power Module: The company will develop an ATP-generating module that allows for faster production and higher yields by decoupling power from production processes, facilitating easier access for partners in synthetic biology.
Trade with 70% Backtested Accuracy
Analyst Views on EXOZ
About EXOZ
About the author
Monday 7/7 Insider Buying Report: EXOZ, IAF
Insider Purchases: CEO Michael Heltzen of Exozymes purchased 1,040 shares at $10.22 each, while Director Moritz A. Sell bought $9,000 worth of Aberdeen Australia Equity Fund shares at $4.50 each, marking their first purchases in the past year.
Stock Performance: Exozymes stock is currently trading lower than Heltzen's purchase price, while Aberdeen Australia Equity Fund has seen a slight decline of 0.9% on the same day.
Bringing clarity and precision to the cell-free space by introducing exozymes
Introduction of Exozymes: The term 'exozymes' has been introduced in a cover story published in GEN Biotechnology to clarify the concept of cell-free biomanufacturing, which allows for chemical production without living cells. This initiative aims to foster innovation and streamline partnerships in the field.
eXoZymes Inc. Overview: eXoZymes Inc., a pioneer in AI-engineered enzymes, is leading the development of sustainable biomanufacturing methods that replace traditional chemical processes with eco-friendly alternatives, enhancing the scalability and efficiency of producing essential chemicals and medicines.
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
eXoZymes Launches BioClick Initiative: eXoZymes Inc. has introduced BioClick, a project aimed at enhancing enzyme engineering for advanced chemical reactions, supported by a $300K NIH grant. This initiative focuses on group transfer reactions and aims to revolutionize the creation of medicines and nutraceuticals.
Advancements in Enzyme Engineering: The BioClick approach incorporates artificial intelligence and high-throughput screening to accelerate the development of new drugs and improve existing ones, potentially unlocking previously inaccessible small molecules for medical applications.
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
Leadership Appointment: eXoZymes Inc. has appointed Damien Perriman as Chief Commercial Officer to drive commercial growth and partnerships, leveraging his extensive experience in biotechnology commercialization.
Innovative Biomanufacturing: The company focuses on developing AI-engineered enzymes, known as exozymes, which aim to revolutionize sustainable chemical production by overcoming limitations of traditional methods and enhancing scalability.
eXoZymes Inc trading resumes
Trading Resumption: eXoZymes (EXOZ) Inc has resumed trading after a halt due to volatility concerns and leadership changes within the company.
Leadership Changes: The company's president and chairman, Hayat, is transitioning out of his roles as part of the recent organizational changes.
eXoZymes Inc trading halted, volatility trading pause
Trading Activity: eXoZymes Inc experienced a trading halt due to volatility, but trading has since resumed following leadership changes within the company.
Leadership Changes: The president and chairman of eXoZymes, Hayat, is transitioning out of their roles as part of the company's restructuring.
Monday 7/7 Insider Buying Report: EXOZ, IAF
Insider Purchases: CEO Michael Heltzen of Exozymes purchased 1,040 shares at $10.22 each, while Director Moritz A. Sell bought $9,000 worth of Aberdeen Australia Equity Fund shares at $4.50 each, marking their first purchases in the past year.
Stock Performance: Exozymes stock is currently trading lower than Heltzen's purchase price, while Aberdeen Australia Equity Fund has seen a slight decline of 0.9% on the same day.
Bringing clarity and precision to the cell-free space by introducing exozymes
Introduction of Exozymes: The term 'exozymes' has been introduced in a cover story published in GEN Biotechnology to clarify the concept of cell-free biomanufacturing, which allows for chemical production without living cells. This initiative aims to foster innovation and streamline partnerships in the field.
eXoZymes Inc. Overview: eXoZymes Inc., a pioneer in AI-engineered enzymes, is leading the development of sustainable biomanufacturing methods that replace traditional chemical processes with eco-friendly alternatives, enhancing the scalability and efficiency of producing essential chemicals and medicines.
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant
eXoZymes Launches BioClick Initiative: eXoZymes Inc. has introduced BioClick, a project aimed at enhancing enzyme engineering for advanced chemical reactions, supported by a $300K NIH grant. This initiative focuses on group transfer reactions and aims to revolutionize the creation of medicines and nutraceuticals.
Advancements in Enzyme Engineering: The BioClick approach incorporates artificial intelligence and high-throughput screening to accelerate the development of new drugs and improve existing ones, potentially unlocking previously inaccessible small molecules for medical applications.
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
Leadership Appointment: eXoZymes Inc. has appointed Damien Perriman as Chief Commercial Officer to drive commercial growth and partnerships, leveraging his extensive experience in biotechnology commercialization.
Innovative Biomanufacturing: The company focuses on developing AI-engineered enzymes, known as exozymes, which aim to revolutionize sustainable chemical production by overcoming limitations of traditional methods and enhancing scalability.
eXoZymes Inc trading resumes
Trading Resumption: eXoZymes (EXOZ) Inc has resumed trading after a halt due to volatility concerns and leadership changes within the company.
Leadership Changes: The company's president and chairman, Hayat, is transitioning out of his roles as part of the recent organizational changes.
eXoZymes Inc trading halted, volatility trading pause
Trading Activity: eXoZymes Inc experienced a trading halt due to volatility, but trading has since resumed following leadership changes within the company.
Leadership Changes: The president and chairman of eXoZymes, Hayat, is transitioning out of their roles as part of the company's restructuring.
